AmpliPhi Biosciences to Participate in Upcoming Conferences

SAN DIEGO–(BUSINESS WIRE)– AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the
development of bacteriophage-based antibacterial therapies to treat
drug-resistant infections, today announced that company management will
participate in two upcoming scientific and investor conferences:

• Rodman & Renshaw 18th Annual Global Investment Conference
  (September 11-13, New York)
  AmpliPhi CEO M. Scott Salka will
  present on Tuesday, September 13 from 4:15 to 4:40 p.m. EDT. Mr. Salka
  will discuss key corporate milestones in addition to reviewing
  AmpliPhi’s pipeline.

• Anti-Infectives Rx (September 21, Boston)
  AmpliPhi CEO M.
  Scott Salka will participate in a panel discussion titled “Tackling
  Resistance: The Promise and The Challenge” on September 21 from 9:00
  to 9:30 a.m. EDT.

For more information, visit www.ampliphibio.com.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (NYSEMKT: APHB) is a biotechnology
company focused on the development and commercialization of novel
bacteriophage-based antibacterial therapeutics. AmpliPhi’s product
development programs target infections that are often resistant to
existing antibiotic treatments. AmpliPhi is currently conducting a Phase
1 clinical trial of AB-SA01 for the treatment of S. aureus in
chronic rhinosinusitis patients and another Phase 1 clinical trial to
evaluate the safety of AB-SA01 when administered topically to the intact
skin of healthy adults. AmpliPhi expects to report final data for both
trials by the end of 2016. AmpliPhi is also developing bacteriophage
therapeutics targeting P. aeruginosa and C.
difficile in collaboration with a number of leading organizations
focused on the advancement of bacteriophage-based therapies.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific
for the bacterial hosts they infect. They can rapidly kill their host,
amplifying themselves in the process. Bacteriophage are unaffected by
antibiotic resistance and are able to disrupt bacterial biofilms. Such
biofilms are a major line of defense for bacteria, contributing to
antibiotic resistance. Bacteriophage are able to penetrate biofilms and
replicate locally to high levels, to produce strong local therapeutic
effects.

Forward Looking Statements

Statements in this press release that are not statements of historical
fact are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include, without limitation, statements about the expected
timing for reporting data from AmpliPhi’s ongoing AB-SA01 trials, the
potential use of bacteriophages to treat bacterial infections, including
infections that do not respond to antibiotics, and AmpliPhi’s
development of bacteriophage-based therapies. Words such as “believe,”
“anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements, though not all forward-looking statements
necessarily contain these identifying words. These forward-looking
statements are based upon AmpliPhi’s current expectations and involve a
number of risks and uncertainties, including the risks and uncertainties
described in AmpliPhi’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2016, as filed with the Securities and Exchange
Commission. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as
a result of these risks and uncertainties. You are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. All forward-looking
statements are qualified in their entirety by this cautionary statement,
and AmpliPhi undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after the
date of this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160912006377/en/